Grünenthal Joins Munich-based Cluster for Nucleic Acid Therapeutics Aachen, Germany – Grünenthal, a global leader in pain management and related diseases, announced today its official partnership with the Cluster for Nucleic Acid Therapeutics Munich (CNATM) on Thursday, July 16, 2026. This collaboration will bring together leading universities, research institutions, biotech companies…
No responses yet